Monash IVF Group Full Year 2024 Earnings: EPS Misses Expectations

Monash IVF Group (ASX:MVF) Full Year 2024 Results

Key Financial Results

• Revenue: AU$255.2m (up 20% from FY 2023).
• Net loss: AU$6.53m (down by 130% from AU$21.8m profit in FY 2023).
• AU$0.017 loss per share (down from AU$0.056 profit in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Monash IVF Group EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates.

Looking ahead, revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Healthcare industry in Australia.

Performance of the Australian Healthcare industry.

The company's shares are down 11% from a week ago.

Risk Analysis

Before you take the next step you should know about the 1 warning sign for Monash IVF Group that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.